Mylan Plans Summer Launch For Advair Generic, Now Called Wixela Inhub
Wixela Inhub could be the first interchangeable generic version of the blockbuster asthma drug on the US market if it is approved by FDA.
You may also be interested in...
The latest drug development news and highlights from our FDA Performance Tracker.
Although it’s not yet clear if an interchangeable version of the respiratory blockbuster will be approved by FDA, CEO Andrew Witty prepared investors to expect a hit, forecasting that a mid-year launch could significantly reduce revenues.
Takeda’s Velcade, Pfizer’s Viagra and Gilead’s Viread are among the brand drugs expected to face generic competition in the US for the first time in 2017. One unknown is if FDA will approve Mylan’s or Hikma’s ANDAs for a generic version of GSK’s Advair.